EHA 2017 | Inotuzumab as a potential treatment for elderly patients with ALL
Philip Thompson, MD, from The University of Texas MD Anderson Center, Houston, TX, USA, guides us through his team’s investigation on effectively treating elderly patients with acute lymphoblastic leukemia (ALL), who do not tolerate intensive chemotherapy well. He describes a regimen whereby the doses of chemotherapeutic drugs are highly reduced to raise the tolerance of patients towards chemotherapy, and the addition of novel agents such as blinatumomab and inotuzumab are included, with the aim of achieving effective treatment (NCT01371630). Overall, he states that the study has achieved positive results, with high rates of complete remission and MRD activity, although there are some side effects associated with this new regimen. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
